Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AASDH
REST API REST API
Homo sapiens
AASDH is differentially expressed in 165 experiments: 72 organism parts: accumbens, adrenal gland cortex, ... (70 more);, 70 disease states: normal, breast carcinoma, ... (68 more);, 56 cell types 275 cell lines 22 compound treatments and 52 other conditions.
Synonyms ACSF4, NRPS998, LYS2
Orthologs AASDH (Bos taurus)   aasdh (Danio rerio)   Aasdh (Mus musculus)   ENSCING00000009136 (Ciona intestinalis)   LYS2 (Saccharomyces cerevisiae)   AASDH (Gallus gallus)   Aasdh (Rattus norvegicus)   U26 (Drosophila melanogaster)   aasdh (Xenopus laevis)   AASDH (Canis familiaris)   (Compare orthologs)
Gene Ontology Term ligase activity, fatty acid metabolic process, cofactor binding, metabolic process, acyl carrier activity, acid-thiol ligase activity, ATP binding, lipid metabolic process, nucleotide binding, catalytic activity
InterPro Term AMP-dep_Synth/Lig, PQQ_beta_propeller_repeat, Acyl_carrier_prot-like, Phsphopanteth-bd
UniProt Accession D6RJA2, Q4L235, E9PH98
Search EB-eye ENSG00000157426
Show more properties
Experimental Factors
Organism part

studied in E-MTAB-37, E-AFMX-5, E-GEOD-22541, E-GEOD-18105, E-GEOD-20950, ... (11 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-19639, E-GEOD-29119, E-GEOD-24147, E-GEOD-19480, ... (21 experiments)

Factor Value U/D Experiments
HT1080
2
E-MTAB-37, E-GEOD-20089
HCC2218
1
E-MTAB-37
MKN74
1
E-GEOD-15460
NA19193
1
E-GEOD-19480
RL952
1
E-MTAB-37
SW962
1
E-MTAB-37
269 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-20677, E-GEOD-4219, E-GEOD-13987, E-GEOD-11755, ... (26 experiments)

Factor Value U/D Experiments
mononuclear
2
E-GEOD-13987, E-GEOD-26672
liver cancer
1
E-GEOD-21154
adipocyte
1
E-AFMX-5
adult native RPE from 78 y.o. donor
1
E-GEOD-18811
adult native RPE from 89 y.o. donor
1
E-GEOD-18811
vascular smooth muscle cell
1
E-TABM-130
50 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-2069, E-GEOD-22148, E-MEXP-2280, ... (33 experiments)

Factor Value U/D Experiments
breast carcinoma
1
2
E-TABM-276, E-MTAB-37, E-GEOD-5823
chronic myelogenous leukemia
1
E-MTAB-37
Renal oncocytoma
1
E-GEOD-19982
Burkitt's lymphoma
1
1
E-MTAB-37
Becker muscular dystrophy
1
1
E-GEOD-3307
Mantle cell lymphoma
1
E-GEOD-18736
64 more value(s).


Compound treatment

studied in E-GEOD-15205, E-TABM-782, E-TABM-868, E-GEOD-15811, E-GEOD-5099, ... (13 experiments)

Factor Value U/D Experiments
estradiol
1
E-GEOD-20081
bacterial endotoxin
1
E-GEOD-3284
control
1
E-GEOD-3284
control - IL-1b
1
E-GEOD-7216
TNF
1
E-GEOD-15205
no estradiol
1
E-GEOD-20081
16 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2359

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (6 experiments)

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-MEXP-421, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

Growth condition
studied in E-MEXP-2657, E-GEOD-21612, E-GEOD-20540, E-GEOD-9764, E-MEXP-2146 ... (5 experiments)

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-176, E-TABM-740, E-MEXP-2069, ... (22 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1657, E-GEOD-17636

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-MEXP-1857, E-MEXP-1315

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-MEXP-973, E-GEOD-19246

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541

Processing time: 0.436 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM